HK1216850A1 - 抗ntb-a抗體及相關的組合物和方法 - Google Patents

抗ntb-a抗體及相關的組合物和方法 Download PDF

Info

Publication number
HK1216850A1
HK1216850A1 HK16104822.8A HK16104822A HK1216850A1 HK 1216850 A1 HK1216850 A1 HK 1216850A1 HK 16104822 A HK16104822 A HK 16104822A HK 1216850 A1 HK1216850 A1 HK 1216850A1
Authority
HK
Hong Kong
Prior art keywords
ntb
antibodies
disclosed
methods
related compositions
Prior art date
Application number
HK16104822.8A
Other languages
English (en)
Chinese (zh)
Inventor
Tim Lewis
Che-Leung Law
Original Assignee
Seattle Genetics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Genetics, Inc. filed Critical Seattle Genetics, Inc.
Publication of HK1216850A1 publication Critical patent/HK1216850A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK16104822.8A 2012-12-21 2013-12-20 抗ntb-a抗體及相關的組合物和方法 HK1216850A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261745239P 2012-12-21 2012-12-21
US201261745239P 2012-12-21
PCT/US2013/077264 WO2014100740A1 (en) 2012-12-21 2013-12-20 Anti-ntb-a antibodies and related compositions and methods

Publications (1)

Publication Number Publication Date
HK1216850A1 true HK1216850A1 (zh) 2016-12-09

Family

ID=50979291

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16104822.8A HK1216850A1 (zh) 2012-12-21 2013-12-20 抗ntb-a抗體及相關的組合物和方法

Country Status (10)

Country Link
US (4) US9708404B2 (https=)
EP (1) EP2934585B1 (https=)
JP (4) JP6449777B2 (https=)
CN (2) CN105188749B (https=)
AU (1) AU2013364043B2 (https=)
CA (1) CA2893977C (https=)
EA (1) EA031025B1 (https=)
HK (1) HK1216850A1 (https=)
IL (2) IL239211B (https=)
WO (1) WO2014100740A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2693310C (en) * 2007-08-02 2018-11-27 Arresto Biosciences, Inc. Lox and loxl2 inhibitors, antibodies and uses thereof
AU2013364043B2 (en) * 2012-12-21 2018-01-04 Seagen Inc. Anti-NTB-A antibodies and related compositions and methods
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US10428159B2 (en) * 2014-09-09 2019-10-01 Board Of Regents, The University Of Texas System Blocking monoclonal antibodies to AGR2 and its receptor C4.4A
CN106470697B (zh) * 2014-09-16 2019-10-25 兴盟生物医药(苏州)有限公司 抗egfr抗体以及其用途
MX388698B (es) * 2014-09-30 2025-03-20 Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts Moleculas de enlace, especialmente anticuerpos, enlazadas a l1cam(cd171).
EP3212668B1 (en) 2014-10-31 2020-10-14 AbbVie Biotherapeutics Inc. Anti-cs1 antibodies and antibody drug conjugates
AU2015358615B2 (en) 2014-12-04 2021-08-05 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute myeloid leukemia
MX389805B (es) 2015-05-20 2025-03-11 Janssen Biotech Inc Anticuerpos anti-cd38 para el tratamiento de amiloidosis de cadena ligera y otras enfermedades malignas hematológicas positivas para cd38.
US20170044265A1 (en) * 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
PT3316909T (pt) * 2015-06-30 2023-11-22 Seattle Genetics Inc Anticorpos anti-ntb-a e composições e métodos relacionados
DK3827845T3 (da) 2015-11-03 2022-05-23 Janssen Biotech Inc Subkutane formuleringer af anti-cd38-antistoffer og anvendelser deraf
JP2019527678A (ja) 2016-06-28 2019-10-03 ユーエムセー・ユトレヒト・ホールディング・ベー・フェー ＣＤ３８に特異的に結合する抗体によるＩｇＥ媒介疾患の治療
JP2021502961A (ja) 2017-10-31 2021-02-04 ヤンセン バイオテツク，インコーポレーテツド 高リスク多発性骨髄腫の治療方法
CA3091181A1 (en) * 2018-02-13 2019-08-22 Precision Biologics, Inc. Methods and compositions for targeting treg cells
CN114008077B (zh) 2019-07-03 2024-10-29 牛津生物疗法有限公司 抗体和使用方法
WO2021066869A1 (en) * 2019-10-04 2021-04-08 TAE Life Sciences Antibody compositions comprising fc mutations and site-specific conjugation properties
US20230092356A1 (en) 2019-12-06 2023-03-23 Thoas Fioretos Novel agents and uses thereof
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5515508A (en) 1993-12-17 1996-05-07 Taligent, Inc. Client server system and method of operation including a dynamically configurable protocol stack
WO1996036361A1 (en) * 1995-05-18 1996-11-21 The Regents Of The University Of Michigan Dna binding antibodies
MA24512A1 (fr) 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
WO2001053466A1 (en) 1999-12-23 2001-07-26 Hyseq, Inc. Methods and materials relating to semaphorin-like polypeptides and polynucleotides
EP1252333A4 (en) 2000-01-25 2005-01-05 Nuvelo Inc METHODS AND SUBSTANCES RELATING TO CD84-TYPE POLYPEPTIDES AND POLYNUCLEOTIDES
WO2001079454A1 (en) 2000-04-13 2001-10-25 Smithkline Beecham Corporation Novel compounds
AU2001274888A1 (en) 2000-05-19 2001-12-03 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
US6464770B1 (en) 2000-08-08 2002-10-15 Advanced Minerals Corporation Perlite products with controlled particle size distribution
CA2632702A1 (en) 2000-09-01 2002-03-28 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7795412B2 (en) 2000-09-15 2010-09-14 Genentech, Inc. Nucleic acids encoding PRO6308 polypeptides and related vectors and host cells
US20030180888A1 (en) 2000-11-03 2003-09-25 Millennium Pharmaceuticals, Inc. CD2000 and CD2001 molecules, and uses thereof
EP1223218A1 (en) 2000-11-03 2002-07-17 Millennium Pharmaceuticals, Inc. CD2000 and CD2001 molecules and uses thereof
US7892730B2 (en) 2000-12-22 2011-02-22 Sagres Discovery, Inc. Compositions and methods for cancer
JP2004533222A (ja) 2001-03-12 2004-11-04 インサイト・ゲノミックス・インコーポレイテッド 免疫グロブリンスーパーファミリータンパク質
CA2454185A1 (en) 2001-07-19 2003-01-30 Innate Pharma Ntb-a, a surface molecule involved in natural killer cells activity
MXPA04001986A (es) 2001-08-29 2004-06-07 Genentech Inc Composiciones y metodos para el tratamiento de enfermedades relacionadas a la inmunidad.
US20060194265A1 (en) 2001-10-23 2006-08-31 Morris David W Novel therapeutic targets in cancer
CA2476555A1 (en) 2002-02-14 2003-08-21 Nuvelo, Inc. Methods of therapy and diagnosis
EP2332956A1 (en) 2002-07-08 2011-06-15 Genentech, Inc. Antibody binding to PRO71238
SI1545613T1 (sl) 2002-07-31 2011-11-30 Seattle Genetics Inc Avristatinski konjugati in njihova uporaba za zdravljenje raka avtoimunske bolezni ali infekcijskebolezni
WO2004016733A2 (en) 2002-08-16 2004-02-26 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
AU2003303305A1 (en) 2002-10-02 2004-09-30 Nuvelo,Inc. Novel nucleic acids and polypeptides
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US7498298B2 (en) 2003-11-06 2009-03-03 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
WO2005108415A2 (en) 2004-04-30 2005-11-17 Biogen Idec Ma Inc. Membrane associated molecules
BRPI0513959A (pt) 2004-07-30 2008-05-20 Rinat Neuroscience Corp anticorpos dirigidos contra o peptìdeo beta-amilóide, suas composições farmacêuticas, kit e métodos de fabricação dos mesmos
JP5171621B2 (ja) 2005-07-07 2013-03-27 シアトル ジェネティックス， インコーポレイテッド フェニルアラニン側鎖修飾をｃ末端に有するモノメチルバリン化合物
US8871720B2 (en) 2005-07-07 2014-10-28 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus
BRPI0617546A2 (pt) * 2005-09-26 2011-07-26 Medarex Inc conjugado de fÁrmaco-anticorpo, formulaÇço farmacÊutica, mÉtodo para matar uma cÉlula de tumor, mÉtodo para retardar ou interromper o crescimento de um tumor em um sujeito mamÍfero e composto
US7847067B2 (en) * 2006-08-28 2010-12-07 ARCA Biopharma Antibodies to NTB-A
WO2009043944A1 (es) * 2007-10-03 2009-04-09 Germans Boada, S.A. Cortadora manual de cerámica
AR068723A1 (es) * 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
RU2476441C2 (ru) 2007-10-19 2013-02-27 Сиэтл Дженетикс, Инк. Cd19-связывающие средства и их применение
MX2011000970A (es) 2008-08-29 2011-03-15 Symphogen As Anticuerpos anti-cd5.
CN102333859B (zh) * 2008-09-16 2015-04-22 三井化学株式会社 由来自植物的原料生产乳酸的方法及生产乳酸的细菌
CA2757237A1 (en) 2009-04-01 2010-10-14 Jane Elizabeth Clarkson Anti-il-23 immunoglobulins
PE20120622A1 (es) 2009-06-17 2012-05-26 Abbott Biotherapeutics Corp Anticuerpos anti-vegf y sus usos
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
US8303093B2 (en) * 2009-12-15 2012-11-06 Xerox Corporation Print head having a polymer layer to facilitate assembly of the print head
EP2526115B1 (en) 2010-01-18 2018-08-01 Novo Nordisk Health Care AG Purification of blood coagulation factors
UA108227C2 (xx) * 2010-03-03 2015-04-10 Антигензв'язуючий білок
KR101820987B1 (ko) 2010-04-15 2018-01-22 프로제닉스 파머슈티컬스, 인코포레이티드 클로스트리듐 디피실리 관련 감염 및 질병의 치료를 위한 항체
US9243057B2 (en) * 2010-08-31 2016-01-26 The Regents Of The University Of California Antibodies for botulinum neurotoxins
PH12016502073B1 (en) * 2010-11-17 2024-04-05 Chugai Pharmaceutical Co Ltd Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
CN106963947A (zh) 2010-11-22 2017-07-21 伊纳特医药股份有限公司 Nk细胞调节治疗和用于治疗血液恶性疾病的方法
AP2014007415A0 (en) 2011-07-11 2014-02-28 Glenmark Pharmaceuticals Sa Antibodies that bind to OX40 and their uses
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
AU2013364043B2 (en) * 2012-12-21 2018-01-04 Seagen Inc. Anti-NTB-A antibodies and related compositions and methods
EP2824112B1 (en) * 2013-07-10 2016-12-21 Miltenyi Biotec GmbH Method for inducing proliferation of Natural Killer cells by mobile nanomatrices
PT3316909T (pt) * 2015-06-30 2023-11-22 Seattle Genetics Inc Anticorpos anti-ntb-a e composições e métodos relacionados

Also Published As

Publication number Publication date
EP2934585A4 (en) 2016-07-13
IL239211A0 (en) 2015-07-30
JP6817674B2 (ja) 2021-01-20
CN107880126A (zh) 2018-04-06
US20170320944A1 (en) 2017-11-09
AU2013364043A1 (en) 2015-06-18
EP2934585B1 (en) 2018-06-13
EA031025B1 (ru) 2018-11-30
IL271305A (en) 2020-01-30
CN105188749A (zh) 2015-12-23
US9708404B2 (en) 2017-07-18
CA2893977A1 (en) 2014-06-26
CN107880126B (zh) 2021-03-30
JP2020055870A (ja) 2020-04-09
US20230105802A1 (en) 2023-04-06
JP6449777B2 (ja) 2019-01-09
CA2893977C (en) 2024-02-13
AU2013364043B2 (en) 2018-01-04
JP2016503067A (ja) 2016-02-01
EP2934585A1 (en) 2015-10-28
IL239211B (en) 2020-08-31
US10435468B2 (en) 2019-10-08
EA201591191A1 (ru) 2015-11-30
WO2014100740A1 (en) 2014-06-26
IL271305B (en) 2021-01-31
US20150376276A1 (en) 2015-12-31
CN105188749B (zh) 2017-12-19
US20190375841A1 (en) 2019-12-12
JP2019014752A (ja) 2019-01-31
JP2022066565A (ja) 2022-04-28

Similar Documents

Publication Publication Date Title
HK1216850A1 (zh) 抗ntb-a抗體及相關的組合物和方法
ZA201707869B (en) Anti-ntb-a antibodies and related compositions and methods
CA3019531A1 (en) Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
MX350200B (es) Anticuerpos humanos y conjugados de anticuerpo-farmaco contra cd74.
WO2012149299A3 (en) Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
JOP20210044A1 (ar) الأجسام المضادة لـ cd38
PH12014502406A1 (en) Anti-il-23p19 antibodies
WO2011143318A3 (en) Anti-fgfr2 antibodies
PH12012501793B1 (en) Monoclonal antibodies against c-met
MX347164B (es) Anticuerpos anti-il-36r.
MX2015000863A (es) Anticuerpos anti-siglec-15.
AU2011328009A8 (en) Compounds and methods for treating pain
MX341076B (es) Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados.
WO2013013025A3 (en) Anti-cxcr4 antibodies and methods of use
AR093377A1 (es) Anticuerpos anti-notch y conjugados de anticuerpo-farmaco
AU2012205878A8 (en) miRNA for treating diseases and conditions associated with neo-angiogenesis
PH12013500810B1 (en) Anti-il-23 antibodies
WO2012177595A9 (en) Compositions and methods for the therapy and diagnosis of cancer
NZ599508A (en) Anticoagulant antidotes
WO2010025321A3 (en) Method for treating multiple sclerosis patients with anti-il2r antibodies
EA201390704A1 (ru) Соединения, ингибирующие металлоферменты
WO2013090635A3 (en) Composition and method for the diagnosis and treatment of iron-related disorders
WO2013090633A3 (en) Composition and method for the diagnosis and treatment of iron-related disorders
MY166463A (en) Positive allosteric modulators of nicotinic acetylcholine receptor
EA201390876A1 (ru) Соединения, ингибирующие металлоферменты